About Drugs in Context

Drugs in Context is an open access, peer-reviewed, continuous publication of international standing. It is a member of the Directory of Open Access Journals (https://doaj.org/). It is listed on PubMed and all articles are free-to-view/download immediately on PubMed Central.

Metrics: SJR/Scimago (2018): SJR = 0.92. Equivalent Impact Factor = 1.087; International collaboration = 39.96%; ranked 96/324 pharmacology journals worldwide by SJR ranking (14/65 open access titles).

Articles: we publish high-quality, peer-reviewed original research papers and topical review articles covering the latest evidence and innovations in drug treatment across all therapeutic areas. Other article types are considered.

Peer review: we conduct single-blind external peer review on all manuscripts with comments from at least two peer reviewers. Our aim is to obtain a first editorial decision within 3 weeks of manuscript submission and online publication within 3 weeks of acceptance.

Submit your manuscript: check the 'SUBMISSION' page for full instructions. Submit your manuscript via Manuscript Manager.

Latest Article

Drug therapy for double-hit lymphoma

Vania Phuoc MD, Jose Sandoval-Sus MD, Julio C Chavez MD, MS

Articles 2016

Lanthanum carbonate oral powder: satisfaction, preference and adherence in French and Spanish patients with end-stage renal disease

Michael Keith, Patricia de Sequera, Francois Clair, Riccardo Pedersini

Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis

Christophe Sapin, Ann Hartry, Siddhesh A Kamat, Maud Beillat, Ross A Baker, Anna Eramo

Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond

Elif A Oral

Influenza vaccination: key facts for general practitioners in Europe—a synthesis by European experts based on national guidelines and best practices in the United Kingdom and the Netherlands

George Kassianos, Patricia Blank, Oana Falup-Pecurariu, Ernest Kuchar, Jan Kyncl, Raul Ortiz De Lejarazu, Aneta Nitsch-Osuch, Gerrit A Van Essen

Evaluating cost benefits of combination therapies for advanced melanoma

Ivar S Jensen, Emily Zacherle, Christopher M Blanchette, Jie Zhang, Wes Yin